New HIV Infection
These studies are for people who are recently diagnosed with HIV and have not started taking medications known as Antiretroviral Therapy (ART). For more information about Acute HIV please click here.
A5354
Goal | Analyze the effects of starting Antiretroviral Therapy (ART) at different stages of acute HIV infection on HIV reservoirs and specific immune responses associated with HIV. |
Who is eligible to participate | Men and women older than 18 years of age with acute HIV infection. |
Medication | FDA-approved Genvoya |
Duration | 72 weeks |
Compensation | Visits – $25.00, Optional procedure visits – up to $250, Total – approximately $500. Travel & parking compensation are offered as well. |
PHI 05
Goal | Treatment of Acute HIV infection with one tablet once a day. |
Who is eligible to participate | Men and women older than 18 years of age with acute HIV infection. |
Medication | Fixed-dose combination of Dolutegravir and Epzicom |
Duration | 5 years (medication provided for 2 years) |
Compensation |
A5378
Goal | To evaluate the safety and tolerability of a monoclonal antibody, VRC07-523LS, in people who have never been treated for HIV (treatment naive). |
Who is eligible to participate | HIV infected men and women 18-70 years old who have never received Antiretroviral Therapy (ART). |
Medication | Monoclonal antibody, VRC07-523LS, administered through a single infusion |
Duration | 48 weeks |
Compensation | Visits – $50, Infusion visit with PK (specific kind of blood draw visit) – $150. Total – up to $1,350. Travel & parking compensation are offered as well. |